Update on Breast Implant-Associated Anaplastic Large Cell Lymphoma

AbstractPurpose of ReviewThe US Food and Drug Administration issued a recall of textured breast implants in July 2019 secondary to their association with anaplastic large cell lymphoma. This brief review serves to summarize what is actually known about breast implant associated anaplastic large cell lymphoma.Recent FindingsSince the FDA ’s first preliminary report in 2011, there have been a reported worldwide total of 573 breast implant associated anaplastic large cell lymphoma (BIA-ALCL) cases, including 33 deaths. In addition to halting the implantation of textured implants, the July recall served to increase awareness and vigi lance when caring for patients with a history of textured breast implants. Recommendations continue to be against voluntary implant removal.SummaryIn the setting of the FDA recall, the importance of comprehensive counseling remains paramount. For patients with textured breast implants, it is vital to ensure patient awareness with thorough education on warning signs and the importance of follow-up.
Source: Current Breast Cancer Reports - Category: Cancer & Oncology Source Type: research

Related Links:

We report a case of breast implant-associated anaplastic large cell lymphoma in a 70-year old woman, who 21 years previously had undergone bilateral breast augmentation with textured silicone implants. Eleven years later, she had bilateral implant removal with possible implant leak and presence of ‘atypical cells’ in the seroma. She then opted for prophylactic bilateral mastectomy in view of her strong family history of breast cancer and underwent reconstruction with subcutaneous gel implants. Eight months later, the patient noted right breast swelling and peri-implant effusion. The cytology was suspicious fo...
Source: Human Pathology: Case Reports - Category: Pathology Source Type: research
FDA has finally drawn a line in the sand on an issue that has plagued the breast implant industry for years. On Wednesday the U.S. regulatory agency called on Allergan to take specific models of its textured breast implants off the market due to the risk of a rare type of cancer. "To protect individuals from the increased risk of breast implant-associated anaplastic large cell lymphoma (BIA-ALCL) associated with Allergan Biocell textured breast implants, [FDA] requested that Allergan recall its Biocell textured breast implants and tissue expanders," the agency said in a safety communicatio...
Source: MDDI - Category: Medical Devices Authors: Tags: Regulatory and Compliance Source Type: news
(WASHINGTON) — Breast implant maker Allergan Inc. issued a worldwide recall Wednesday for textured models because of a link to a rare form of cancer. The U.S. Food and Drug Administration said it called for the removal after new information showed Allergan’s Biocell breast implants with a textured surface account for a disproportionate share of rare lymphoma cases. The move follows similar action in France, Australia and Canada. The FDA is not recommending women with the implants have them removed if they are not experiencing problems. Biocell implants feature a textured surface designed to prevent slippage and...
Source: TIME: Health - Category: Consumer Health News Authors: Tags: Uncategorized Cancer onetime Source Type: news
AbstractImplant-associated breast cancer is a well-described pathologic process that occurs in patients with breast implants. Anaplastic large cell lymphoma (ALCL), the most prominent malignancy associated with breast implants, has been extensively described, while literature regarding non-ALCL implant-associated cancers is limited. Here, we present a rare case of a 55-year-old female with squamous cell carcinoma (SCC) of the breast and chest following multiple breast revision surgeries who underwent tumor resection with a unique soft tissue reconstruction utilizing two anterolateral thigh (ALT) flaps in a flow-through manner.
Source: European Journal of Plastic Surgery - Category: Cosmetic Surgery Source Type: research
A panel of experts convened by the FDA yesterday said that there’s not enough data to pull textured breast implants from the market over concerns that they may be linked to a type of immune system cancer, according to an AP News report. The recommendation comes from the first day of a two-day panel meeting discussing the risks associated with breast implant devices, reviewing current study data and exploring how to best track and treat the cancer, and other issues, the devices have been tied to. The FDA only began reporting on the cancer, known as breast implant-associated anaplastic large cell lymphoma, and its link...
Source: Mass Device - Category: Medical Devices Authors: Tags: Cosmetic/Aesthetic Food & Drug Administration (FDA) Oncology Women's Health Source Type: news
The FDS has warned pharmaceutical companies in the past about their use of paid surrogates on social media sites like Instagram to promote their products (see:Pharmaceutical Companies Continue to Experiment with Social Media;FDA Issues Warning Letter to Drug Company about Use of Instagram;GlaxoSmithKline Mines Social Media for Information about Adverse Drug Events). This issue has recently returned to the news (see:The latest Instagram influencer frontier? Medical promotions. Big pharma is partnering with influencers to sell new drugs and medical devices). Below is an excerpt from the article. It's long and provides ma...
Source: Lab Soft News - Category: Laboratory Medicine Authors: Source Type: blogs
(WASHINGTON) — U.S. health officials say doctors should be on the lookout for a rare cancer linked to breast implants after receiving more reports of the disease. The Food and Drug Administration sent a letter late Wednesday to family doctors, nurses and other health professionals warning about the form of lymphoma in breast implant patients. In suspected cases, the FDA recommends laboratory testing to confirm or rule out of the disease. It’s the first time regulators have issued such a warning to doctors other than plastic surgeons. The disease is not breast cancer, but usually forms in the scar tissue that fo...
Source: TIME: Health - Category: Consumer Health News Authors: Tags: Uncategorized Cancer onetime Source Type: news
Breast implants are causing more deadly breast cancer among women, according to the U.S. Food and Drug Administration.
Source: Health News - UPI.com - Category: Consumer Health News Source Type: news
Conclusions: In situ BIA-ALCLs have an indolent clinical course and remain in complete remission mainly after implant removal. Infiltrative BIA-ALCLs have a more aggressive clinical course. It is therefore critical to perform a rigorous staging using multi-imaging modality including TEP at baseline. Multiple implants could favor the occurrence of BIA-ALCL. New insights into the biology of BIA-ALCL might translate into more targeted and effective therapies in refractory or relapsed patients. The modalities of breast monitoring and reconstruction remain open questions for those patients.DisclosuresLe Bras: Amgen: Consultancy...
Source: Blood - Category: Hematology Authors: Tags: 624. Hodgkin Lymphoma and T/NK Cell Lymphoma-Clinical Studies: Poster I Source Type: research
CONCLUSION: The risk that a woman with breast implants will develop a primary anaplastic large-cell lymphoma is estimated at 0.35 to 1 case per million persons per year. The incidence of implant-associated ALCL is thus very low, yet nevertheless markedly higher than that of other primary lymphomas of the breast. Because of the low case numbers, recommendations for the diagnostic evaluation and treatment of this entity have not been adequately evaluated. Treatment with primary curative intent for BIA-ALCL confers a much better prognosis than when performed for a systemic ALCL. Whenever a patient with a breast implant presen...
Source: Deutsches Arzteblatt International - Category: General Medicine Tags: Dtsch Arztebl Int Source Type: research
More News: Breast Augmentation | Breast Cancer | Cancer | Cancer & Oncology | Education | Food and Drug Administration (FDA) | Lymphoma | Plastic Surgery | Universities & Medical Training | Warnings